Skip to main content
. 2020 Jan 1;10(2):567–584. doi: 10.7150/thno.36777

Figure 3.

Figure 3

In vivo quantification and positron emission tomography (PET) imaging of 89Zr-labelled nanostar 8 (p([89Zr]Zr-DFO-AEA-co-OEGA-co-[Gd3+]VDMD)). (A) Uptake study scheme of 89Zr-labelled nanostars in BALB/c mice, isografted with CT26 colon cancer (high EPR) or xenografted with BxPC3 pancreatic cancer (low EPR) cells. (B-C) Representative coronal and maximum intensity projection (MIP) PET images of BALB/c mice (n=5 per study) carrying CT26 or BxPC3 tumours, 3 days after injection of 89Zr-labelled nanostars (~10 MBq, MA = 64 GBq/µmol). High accumulation of the 89Zr-labelled nanostars was observed in CT26 isografts, whereas low and mainly peripheral accumulation was observed in BxPC3 xenografts, indicating passive tumour uptake via the EPR effect. Scale bars are in %ID/g. (D) Biodistribution profile 3 days after injection of 89Zr-labelled nanostars in BALB/c mice isografted with CT26 colon cancer cells. Highest accumulation was observed in tumour tissue and spleen. S.I.: small intestine, L.I.: large intestine. (E) Comparison of maximum uptake values in volumes of interest (VOIs) of CT26 and BxPC3 tumours. Uptake of 89Zr-labelled in CT26 (high EPR) isografts was significantly higher than uptake in BxPC3 (low EPR) xenografts, as determined by the independent-samples t-test (P=0.001).